search

Active clinical trials for "Precursor Cell Lymphoblastic Leukemia-Lymphoma"

Results 1421-1430 of 1817

Comparison Between Cyclophosphamide and Combination of Methotrexate + Calcineurin Inhibitor for...

Acute Myelogenous LeukemiaAcute Lymphoid Leukemia4 more

The purpose of this study is to determine whether cyclophosphamide post bone marrow transplant increases the rate of patients alive, in remission and without immunosuppression, one year after transplant, when compared with the combination of methotrexate and calcineurin inhibitor

Terminated13 enrollment criteria

Growth Factor Signature (GFS) Pilot Study (MK0000-098)(COMPLETED)

Blast Phase Philadelphia Chromosomes Positive (Ph+) Chronic Myelogenous Leukemia (CML)Philadelphia Chromosome Positive (Ph+) Acute Lymphocytic Leukemia (ALL)

This study will evaluate a gene expression signature (Growth Factor Signature [GFS]) as a biomarker for response/resistance to BRC-ABL oncogene inhibitors.

Terminated18 enrollment criteria

Retrospective Observational Study on Infective Complications and Outcome of Patients With ALL Treated...

Acute Lymphoblastic LeukemiaInfections3 more

The goal of this observational study is to learn about infectious complications in patients affected by B-cell acute lymphoblastic leukemia treated with inotuzumab-ozogamicin (INO). The main question it aims to answer is: • incidence of infectious complications (bacterial, fungal, viral) in patients receiving inotuzumab ozogamicin up to 60 days after the end of treatment

Not yet recruiting4 enrollment criteria

CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies

Hematologic DiseasesHematologic Malignancy4 more

This is a Phase II trial testing disease-specific myeloablative conditioning regimens for preparatory cytoreduction of patients receiving allogeneic HLA-compatible related or unrelated transplants of GCSF-mobilized peripheral blood stem cells (PBSC) depleted of T-cells by positive selection of CD34+ progenitor cells using the CliniMACS system. The CliniMACS Fractionation system is a method that positively selects CD34+ progenitor cells from PBSC by immunoadsorption of cells binding on anti CD34 monoclonal antibody to paramagnetic beads, which can then be isolated by passage through a magnetized column and released by agitation of beads. Two conditioning regimens have been used successfully with an alternative similar system, isolex, which is no longer being manufactured.

Withdrawn34 enrollment criteria

Determining the Mechanisms of Loss of CAR T Cell Persistence

Acute Lymphoblastic Leukemia With Failed RemissionAcute Lymphoblastic Leukemia Not Having Achieved Remission6 more

A prospective observational study of pediatric and young adult acute lymphoblastic leukaemia (ALL) patients treated with CD19 chimeric antigen receptor T-cells (CAR-T cells). The study will examine changes in CAR-T persistence over time and causal factors.

Not yet recruiting4 enrollment criteria

StemRegenin-1 Expanded vs Unexpanded UCB for High Risk Heme Malignancies

Acute Myeloid LeukemiaAcute Lymphocytic Leukemia2 more

This is an open label, interventional, randomized phase II trial comparing StemRegenin-1 (SR-1) cultured umbilical cord blood (experimental arm) to unmanipulated umbilical cord blood (standard of care arm) transplantation after a myeloablative CY/FLU/TBI conditioning. A 2:1 randomization will be employed with a higher chance of being assigned to the experimental arm.

Withdrawn33 enrollment criteria

Effect of Different Exercises on Quality of Life of Leukemia Patients.

Quality of LifeAcute Lymphoblastic Leukemia1 more

To compare between modified strength training program and aerobic exercises on quality of life on children with Acute Lymphoblastic Leukemia. To compare between modified strength training program and aerobic exercises on functional capacity on children with Acute Lymphoblastic Leukemia.

Completed18 enrollment criteria

Metformin Reduce the Relapse Rate on Patients With B-cell Precursor (Ph+ Negative) Acute Lymphoblastic...

Acute Lymphoblastic Leukemia

Metformin's Antitumor activity were identified from differens diabetic patients trials, mainly associated to its mechanism of action and protein - kinase AMPK (AMP-activated protein kinase) activation. According to Cancer and Diabetes International Consensus from 2012, diabetes increases the risk for developping cancer and metformin has an protector effect against cancer cells and has an impact on overall survival. Chemotherapy drug resistance induces treatment fail in oncology. Metformin increases AMPK levels, blocks PI3K (phosphatidylinositol 3- kinase)/ AKT /mTOR(mammailian Target of Rapamycin) pathway but few evidence associated with drug resistance gene expression. This is an, experimental one-center study that pretends to stablish the effect of adding metformin 850 mg PO three times a day over the multi-drug resistance gene expression (ABCB1) in de novo Acute Lymphoblastic Leukemia in one 7-days cycle with prednisone as pre-treatment- and on the induction remission treatment.

Completed21 enrollment criteria

Sleep Hygiene and Relaxation Intervention to Improve Sleep and Fatigue for Children Receiving Maintenance...

SleepFatigue1 more

This pilot randomized controlled trial examined the feasibility, acceptability and effectiveness of an intervention to improve sleep quality and decrease fatigue levels in children with a diagnosis of ALL, during maintenance treatment. Families were randomized to usual care or the intervention. The intervention included a sleep hygiene and relaxation education session with a nurse practitioner, literature for home, two story books, and a follow-up phone call. Self-reported measures were used in addition to actigraphy to measure children's quality and quantity of sleep.

Completed9 enrollment criteria

Evaluation of Therapeutic Video Games for Pre-school Children With Acute Lymphoblastic Leukemia...

Childhood Lymphoblastic Lymphoma

The purpose of this study is to evaluate the effectiveness of therapeutic video game.

Completed6 enrollment criteria
1...142143144...182

Need Help? Contact our team!


We'll reach out to this number within 24 hrs